Sabine Hadida is a pharmacologist and senior vice president at Vertex Pharmaceuticals. She works at Vertex's cystic fibrosis research center in San Diego. She was awarded the Breakthrough Prize in Life Sciences in 2024.
Education
editHadida has a bachelor's degree, master's degree, and Ph.D. in pharmacy from the University of Barcelona, Spain.[1] She worked as a postdoctoral fellow at the University of Pittsburgh studying fluorous chemistry.[1]
Research
editAt Vertex Pharmaceuticals, Hadida led the chemistry team to work on drug treatments for cystic fibrosis and pain.[1] Prior to joining Vertex in 2002, she worked as a research scientist at drug discovery company CombiChem, Inc., which was subsequently acquired by DuPont Pharmaceuticals.[2]
Awards and honors
editHadida has garnered over 30 peer reviewed scientific articles and over 60 U.S. patents.[1] She is the recipient of the 2022 Drug Hunter Award, 2019 Distinguished Scientist Award by the American Chemistry Society, San Diego Chapter, and the 2013 American Chemistry Society Heroes of Chemistry award.[1][3]
In September 2023, she received the 2024 Breakthrough Prize in Life Sciences alongside Paul Negulescu and Frederick Van Goor, for developing treatment for cystic fibrosis.[4]
References
edit- ^ a b c d e "The 21st Annual Wiley Prize in Biomedical Sciences". Events & Lectures. Retrieved 2023-09-27.
- ^ "DuPont To Acquire CombiChem For $95 Million". www.pharmaceuticalonline.com. Retrieved 2023-09-27.
- ^ "Heroes of Chemistry - Archive". American Chemical Society. Retrieved 2023-09-27.
- ^ "Breakthrough Prize – Life Sciences Breakthrough Prize Laureates – Sabine Hadida". breakthroughprize.org. Retrieved 2023-09-27.
This article needs additional or more specific categories. (October 2023) |